Kura Oncology logo

Kura Oncology

KURA | NASDAQ
Chart Builder DCF Calculator
$7.09
-$0.68 (-8.75%)
At close: Nov 16, 2026, 4:00 PM ET
$7.35
+$0.26 (+3.67%)
After-hours: Nov 16, 2026, 7:57 PM ET
-8.75%

No price chart data available for 1D timeframe.

Rating

Updated: Nov 16, 2026
45.6
Fundamentals Average
Market Sentiment Bullish
Moat Narrow
Sector Rank #377/1021 (Top 37%)

Key Statistics

Market Data

Market Cap $651.42M
1D Range
7.07 7.73
52W Range
6.80 13.59

Valuation (TTM)

PE -2.15
PB 36.27
EV/EBITDA -0.64

Valuation (NTM)

Forward PE N/A
Forward PEG -0.19
Price Target $24.00
Loading financial charts...

Profile

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s first commercial product, KOMZIFTI (ziftomenib), a potent, selective, rev...

Sector Healthcare
Industry Biotechnology
Employees 260
IPO Date Sep 16, 2015
Fiscal Year January - December

Latest News

Kura Oncology, Inc. (KURA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

2 months ago · seekingalpha.com

Kura Oncology, Inc. (KURA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Kura Oncology Launches Caspian Therapeutics with $50 Million Financing to Advance Menin Inhibition as a Potential Disease-Modifying Approach for Diabetes

2 months ago · globenewswire.com

Kura Oncology Launches Caspian Therapeutics with $50 Million Financing to Advance Menin Inhibition as a Potential Disease-Modifying Approach for Diabetes
Kura Oncology Appoints Jennifer Fulk as Chief Financial Officer

2 months ago · globenewswire.com

Kura Oncology Appoints Jennifer Fulk as Chief Financial Officer
KURA Stock Gains 37.6% in a Month: Here's What You Need to Know

3 months ago · zacks.com

KURA Stock Gains 37.6% in a Month: Here's What You Need to Know
Kura Oncology to Participate in Three Investor Conferences in September

3 months ago · globenewswire.com

Kura Oncology to Participate in Three Investor Conferences in September
Kura Oncology (KURA) Upgraded to Buy: What Does It Mean for the Stock?

3 months ago · zacks.com

Kura Oncology (KURA) Upgraded to Buy: What Does It Mean for the Stock?
Kura Oncology: 'Strong Buy': Ziftomenib AML Expansions With Different Regimens Could Boost KOMZIFTI's Prospects

3 months ago · seekingalpha.com

Kura Oncology: 'Strong Buy': Ziftomenib AML Expansions With Different Regimens Could Boost KOMZIFTI's Prospects
Kura Oncology CEO Buys 100,000 Shares for $1.2 Million. Does This Large Buy Bode Well for Shares in 2026?

3 months ago · fool.com

Kura Oncology CEO Buys 100,000 Shares for $1.2 Million. Does This Large Buy Bode Well for Shares in 2026?
Kura Oncology (KURA) is a Great Momentum Stock: Should You Buy?

3 months ago · zacks.com

Kura Oncology (KURA) is a Great Momentum Stock: Should You Buy?
Does Kura Oncology (KURA) Have the Potential to Rally 178.55% as Wall Street Analysts Expect?

3 months ago · zacks.com

Does Kura Oncology (KURA) Have the Potential to Rally 178.55% as Wall Street Analysts Expect?

Earnings

Latest Earnings
Nov 10, 2026
EPS
-$0.78
Beat +4.84%
REV
$22.84M
Miss -8.44%
Next Earnings
Mar 4, 2027
EPS Est
Pro
Rev Est
Pro
Earnings Details ➞

Analyst Summary

# of Analysts
7
Consensus
Buy
Price Target
$24.00
Upside
+238.50%
Buy (7)
Hold (0)
Sell (0)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.